Page last updated: 2024-11-08

l 365031

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 365031: CCK antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID196641
CHEMBL ID71950
SCHEMBL ID8977570
MeSH IDM0151908

Synonyms (19)

Synonym
l 365031
CHEMBL71950 ,
(s)-4-bromo-n-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)-benzamide
(r)-4-bromo-n-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)-benzamide
4-bromo-n-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)-benzamide
4-bromo-n-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)-benzamide:0.05c3h6o
bdbm50019204
4-bromo-n-(1-methyl-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)benzamide
1-methyl-3-(4-bromobenzoyl)amino-5-phenyl-3h-1,4-benzodiazepin-2-one
111035-59-7
benzamide, 4-bromo-n-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl)-
l-365,031
4-bromo-n-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl)-benzamide
FHCLUARBHKHIQK-UHFFFAOYSA-N
SCHEMBL8977570
DTXSID50911950
4-bromo-n-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1h-1,4-benzodiazepin-3-yl)benzamide
4-bromo-n-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)benzamide
AKOS040745969

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Data revealed that, in mice, the CCKA receptor antagonist, devazepide (formerly L-364,718, MK-329), produced a clear anxiolytic-like profile with an inverted U-shaped dose-response curve centered around 5 micrograms/kg."( The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice.
Dourish, CT; Hendrie, CA; Neill, JC; Shepherd, JK, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)0.00100.00000.43624.3000AID52414; AID52890
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID52890Binding affinity against cholecystokinin type A receptor of rat pancreas1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Three-dimensional molecular shape analysis-quantitative structure-activity relationship of a series of cholecystokinin-A receptor antagonists.
AID52414Half-maximal inhibition of [125I]CCK-8 binding to cholecystokinin receptor from rat pancreatic tissue1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
AID52280Half-maximal inhibition of [125I]-CCK-8(+) binding to cholecystokinin receptor from guinea pig brain tissue1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
AID78288Half-maximal inhibition of [125I]gastrin binding to guinea pig gastric glands1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (57.14)18.7374
1990's3 (42.86)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.32 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]